By analyzing the expression, prognosis, and sensitivity to cisplatin chemotherapy of these genes in bladder cancer samples from The Cancer Genome Atlas (TCGA) database, c-Myc was identified as the best differential prognostic gene in bladder cancer and was most associated with cisplatin chemotherapy sensitivity. This evidence concerns the gene MYC and urinary bladder cancer.